Group 1 - The company has established a joint investment with AglaeaPharma to set up Guangxi Aglaea, focusing on multi-target small molecule compound drug screening and early disease detection and diagnostic technology development [2] - AglaeaPharma's project platform has developed multiple technology platforms, product pipelines, and a series of products, forming a globally integrated innovative research and development system [2] - The company will continue to monitor the project's progress and fulfill its information disclosure obligations in a timely manner [2]

格隆汇7月30日丨莱美药业(300006.SZ)在互动平台表示，公司目前暂无注射用钙素产品。 （原标题：莱美药业(300006.SZ)：目前暂无注射用钙素产品） ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-035 重庆莱美药业股份有限公司 关于间接控股股东股权结构拟发生变动的提示性公告 本公司、董事会全体成员及相关股东保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广西国控集团为广西国资委的全资子公司，广投集团、广西国控集团和 公司的实际控制人均为广西国资委，本次交易属于间接控股股东的股权结构变动。 截至本公告披露日，公司控股股东仍为广西梧州中恒集团股份有限公司（以下简 称"中恒集团"），公司实际控制人仍为广西国资委，公司的控股股东及实际控 制人均未发生变化。 近日，公司控股股东中恒集团收到间接控股股东广投集团通知，获悉广投集 团股权结构拟发生变动。现将相关情况公告如下： 一、间接控股股东股权结构变动的基本情况 广投集团收到广西国资委的通知，拟将广西国资委持有的广投集团33%股权 无偿划转至广西国控集团。 本次划转完成后，公司控股股东仍为中恒集团，公司实际控制人仍为广西国 资委，广西国控集团将成为广投集团的股东，持有广投集团33%股权，广西国资 委仍为广投集团的控股股东，持有其67%股权。 二、对公司的影响 本次股权结构 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-034 重庆莱美药业股份有限公司 关于获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，重庆莱美药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的注射用吗替麦考酚酯注射液（规格：0.5g）《药品补充申请批 准通知书》，现将有关事宜公告如下： | 药品名称 | 药品通用名称：注射用吗替麦考酚酯 | | | | --- | --- | --- | --- | | | 英文名/拉丁名：Mycophenolate Mofetil for Injection | | | | 剂型 | 注射剂 | | | | 注册分类 | 化学药品 | | | | 原药品批准文号 | 国药准字 H20059282 | | | | 药品注册标准编号 | YBH18072025 | | | | 包装规格 | 1 瓶/盒 | | | | 规格 | 0.5g | | | | 通知书编号 | 2025B03351 | | | | 申请内容 | 仿制药注射剂一致性评价，其他变更事 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-033 重庆莱美药业股份有限公司 关于投资的产业投资基金延长存续期限 暨完成工商登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、产业基金基本情况 重庆莱美药业股份有限公司（以下简称"公司"）于 2018 年与广州赛富立 合资本管理有限公司（以下简称"赛富资本"）、广东立合投资控股有限公司签 署《合伙协议》，共同投资设立广州赛富健康产业投资合伙企业（有限合伙）（以 下简称"赛富健康"），具体内容详见公司在巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于投资设立产业投资基金的公告》（公告编号：2018-035）。 二、产业基金延期情况 赛富健康原经营期限将于2025年7月26日到期，因投资的部分项目未能完全 退出，为保证基金的正常运作和项目的顺利退出，实现合伙人权益，根据《合 伙协议》的约定，经普通合伙人赛富资本提议并由全体合伙人一致决定：同意 延长赛富健康存续期两年，即存续期延长至2027年7月26日，并签署合伙企业相 关文件。近日，赛富健康已完成工商变 ...

Group 1 - The A-share ophthalmology sector experienced a volatile rebound, with Tianmu Pharmaceutical hitting the daily limit up [1] - Other companies such as Xingqi Eye Medicine, Laimei Pharmaceutical, Nuo Silan De, and Daheng Technology also saw increases in their stock prices [1]

Group 1 - The pharmaceutical e-commerce sector saw a rise of 2.00%, ranking 8th among concept sectors, with 124 stocks increasing in value [1] - Notable gainers included Rundu Co., Aosaikang, and Wanbangde, which reached their daily limit up, while Furuishi and Laimei Pharmaceuticals also performed well with increases of 9.55%, 8.48%, and 5.54% respectively [1] - The sector experienced a net inflow of 750 million yuan from main funds, with 83 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Rundu Co. led the net inflow with 145 million yuan, followed by Yipin Hong, Furuishi, and Zhongsheng Pharmaceuticals with net inflows of 98.68 million yuan, 83.98 million yuan, and 70.42 million yuan respectively [2] - In terms of net inflow ratio, Rundu Co. had a leading rate of 42.20%, followed by Zhejiang Zhenyuan and ST Huluwawa at 29.25% and 16.55% respectively [3] Group 3 - The pharmaceutical e-commerce concept had a total of 124 stocks rising, with significant contributions from stocks like Rundu Co. and Aosaikang, which both showed strong performance [1][2] - The overall market sentiment in the pharmaceutical e-commerce sector appears positive, as indicated by the substantial net inflows and the number of stocks experiencing gains [2][3]

Group 1 - The hepatitis concept sector rose by 2.17%, ranking 7th among concept sectors, with 120 stocks increasing in value, including notable gainers such as Rundu Co., Wanbangde, and Lisheng Pharmaceutical, which hit the daily limit [1][2] - The top gainers in the hepatitis concept sector included Guangshantang, Furuishi, and Laimei Pharmaceutical, with increases of 16.55%, 9.55%, and 8.48% respectively [1][2] - The sector experienced a net inflow of 1.831 billion yuan, with 87 stocks receiving net inflows, and 16 stocks exceeding 50 million yuan in net inflow, led by Qianhong Pharmaceutical with a net inflow of 227 million yuan [2][3] Group 2 - The leading stocks by net inflow ratio included Rundu Co. at 42.20%, ST Weiming at 33.93%, and Zhejiang Zhenyuan at 29.25% [3] - The top stocks in the hepatitis concept sector based on net inflow included Qianhong Pharmaceutical, ST Weiming, and Hanyu Pharmaceutical, with respective net inflows of 226.89 million yuan, 168.20 million yuan, and 165.89 million yuan [3][4] - The overall performance of the hepatitis concept sector reflects strong investor interest and significant capital inflows, indicating potential growth opportunities within the sector [2][3]

Group 1 - The concept of Helicobacter pylori has seen an increase of 1.93%, ranking 9th among concept sectors, with 62 stocks rising, including Rundu Co., Aosaikang, and Zhejiang Zhenyuan hitting the daily limit [1][2] - Leading gainers in the Helicobacter pylori sector include Laimei Pharmaceutical, Hanyu Pharmaceutical, and Te Yi Pharmaceutical, with increases of 8.48%, 6.41%, and 5.49% respectively [1] - The sector experienced a net inflow of 774 million yuan from main funds, with 49 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow, led by Hanyu Pharmaceutical with 166 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio are Rundu Co. at 42.20%, Zhejiang Zhenyuan at 29.25%, and ST Huluwa at 16.55% [3][4] - Hanyu Pharmaceutical had a trading volume of 165.89 million yuan with a net inflow ratio of 6.26%, while Rundu Co. had a trading volume of 144.66 million yuan [3][4] - The overall market performance shows a mixed trend, with some stocks like Zhijiang Biology, ST Suwu, and Dongfang Ocean experiencing declines of 6.08%, 5.02%, and 4.23% respectively [6][7]

Core Points - The latest financing balance of the ChiNext market is 367.464 billion yuan, with a week-on-week increase of 3.028 billion yuan, indicating a positive trend in financing activities [1] - A total of 25 stocks saw their financing balances increase by over 10%, while 12 stocks experienced a decline of more than 10% [1] Financing Balance Overview - The total margin balance for ChiNext stocks reached 368.568 billion yuan, marking a continuous increase for six consecutive trading days [1] - The financing balance specifically increased to 367.464 billion yuan, with a week-on-week rise of 3.028 billion yuan [1] - The margin trading balance for short selling decreased to 1.103 billion yuan, reflecting a reduction of 7.6652 million yuan [1] Stocks with Significant Financing Balance Increase - Among the 535 stocks with increased financing balances, the stock with the highest increase is Sanwei Tiandi, which saw a financing balance of 70.6392 million yuan, up 66.35% from the previous day [3] - Other notable stocks with significant increases include Focase Technology and Shanghai Steel Union, with increases of 43.23% and 34.52%, respectively [3] Market Performance of Stocks with Increased Financing - Stocks with financing balance increases averaged a rise of 2.86% on the trading day, with top performers including Sanchuan Wisdom, Yirui Biology, and Focase Technology, which rose by 15.27%, 12.15%, and 11.54% respectively [2] - Conversely, stocks with the largest declines included Pulian Software, Houpu Co., and Hopu Co., with declines of 6.92%, 5.85%, and 3.61% respectively [2] Stocks with Significant Financing Balance Decrease - A total of 400 stocks experienced a decrease in financing balance, with 12 stocks seeing declines of over 10% [4] - The stock with the largest decrease is Tuanluozhe, with a financing balance of 18.9151 million yuan, down 94.06% [4] - Other stocks with significant declines include Laimei Pharmaceutical and Jialian Technology, with decreases of 22.96% and 21.70% respectively [4]